246 related articles for article (PubMed ID: 25695283)
1. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
2. LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway.
Li F; Yang W; Guo D; Hu Z; Xu H; Ye Z
Oncol Rep; 2011 Jun; 25(6):1629-37. PubMed ID: 21431282
[TBL] [Abstract][Full Text] [Related]
3. LRIG1 enhances cisplatin sensitivity of glioma cell lines.
Wang X; Xiao Q; Xing X; Tian C; Zhang H; Ye F; Wan F; Wang B; Guo D; Lei T
Oncol Res; 2012; 20(5-6):205-11. PubMed ID: 23581227
[TBL] [Abstract][Full Text] [Related]
4. Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1.
Li F; Ye ZQ; Guo DS; Yang WM
Oncol Rep; 2011 Aug; 26(2):439-46. PubMed ID: 21567105
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
6. Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.
Chang L; Shi R; Yang T; Li F; Li G; Guo Y; Lang B; Yang W; Zhuang Q; Xu H
J Exp Clin Cancer Res; 2013 Dec; 32(1):101. PubMed ID: 24314030
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
8. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
9. LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway.
Yang JA; Liu BH; Shao LM; Guo ZT; Yang Q; Wu LQ; Ji BW; Zhu XN; Zhang SQ; Li CJ; Chen QX
Int J Clin Exp Pathol; 2015; 8(4):3580-90. PubMed ID: 26097540
[TBL] [Abstract][Full Text] [Related]
10. [Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].
Yan ZJ; Cheng Y; Jiang JH; Hu JS; Shi XD
Zhonghua Wai Ke Za Zhi; 2012 Aug; 50(8):732-6. PubMed ID: 23157908
[TBL] [Abstract][Full Text] [Related]
11. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
[TBL] [Abstract][Full Text] [Related]
12. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated IL-24 expression enhances the chemosensitivity of multidrug-resistantgastric cancer cells to cisplatin.
Mao Z; Bian G; Sheng W; He S; Yang J; Dong X
Oncol Rep; 2013 Nov; 30(5):2288-96. PubMed ID: 23982423
[TBL] [Abstract][Full Text] [Related]
14. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.
Zhou L; Li X; Zhou F; Jin Z; Chen D; Wang P; Zhang S; Zhuge Y; Shang Y; Zou X
Cancer Sci; 2018 Apr; 109(4):1044-1054. PubMed ID: 29450946
[TBL] [Abstract][Full Text] [Related]
16. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.
Goldoni S; Iozzo RA; Kay P; Campbell S; McQuillan A; Agnew C; Zhu JX; Keene DR; Reed CC; Iozzo RV
Oncogene; 2007 Jan; 26(3):368-81. PubMed ID: 16847455
[TBL] [Abstract][Full Text] [Related]
17. Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
Wu X; Hedman H; Bergqvist M; Bergström S; Henriksson R; Gullbo J; Lennartsson J; Hesselius P; Ekman S
Acta Oncol; 2012 Jan; 51(1):69-76. PubMed ID: 21417672
[TBL] [Abstract][Full Text] [Related]
18. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
[TBL] [Abstract][Full Text] [Related]
19. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
20. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]